thenewsfacts.com
  • Home
  • Latest News
  • Trending News
  • Entertainment
  • Technology
  • Sports
  • Business
  • Health
thenewsfacts.comthenewsfacts.com
Font ResizerAa
Search
  • Home
  • Latest News
  • Trending News
  • Entertainment
  • Technology
  • Sports
  • Business
  • Health
Follow US
© thenewsfacts : All Rights Reserved.

Home » CDSCO Extends India’s COVAXIN Shelf Life to 12 Months Now

COVID Vaccines

CDSCO Extends India’s COVAXIN Shelf Life to 12 Months Now

TheNewsFacts
Last updated: November 3, 2021 4:33 pm
TheNewsFacts
Share
CDSCO Extends India's COVAXIN Shelf Life to 12 Months Now
SHARE

The Central Drugs Standard Control Organisation (CDSCO) has approved the extension of Covid-19 vaccine Covaxin Shelf Life to up to 12 months from the date of manufacturing, said Bharat Biotech in a statement on Wednesday.

Bharat Biotech had earlier this year written to India’s drug regulator seeking an extension of the shelf-life of its vaccine. The Hyderabad-based firm said that it submitted necessary real-time stability data of Covaxin to the drug regulator to substantiate its application.

COVAXIN shelf life extended by Indian Regulator

COVAXIN SHELF LIFE
COVAXIN shelf life extended by CDSCO

Currently, Covaxin has an approved shelf-life of six months, which was extended to 9 months, and now the extension is granted for 12 months subject to its storage at two to eight degrees celsius.

Vaccine maker Bharat Biotech on Wednesday said the Central Drugs Standard Control Organisation (CDSCO) has approved the extension of shelf life of its COVID-19 vaccine Covaxin up to 12 months from the date of manufacture.

“The CDSCO has approved the extension of shelf life of Covaxin up to 12 months, from the date of manufacture. This approval of shelf life extension is based on the availability of additional stability data, which was submitted to CDSCO,” Bharat Biotech said in a tweet.

Meanwhile Technical Advisory Group (TAG) of the World Health Organisation (WHO) is likely to decide on Covaxin’s Emergency Use Listing (EUL) on Wednesday.

“The TAG met on 26 October and decided to seek additional clarifications from the Covaxin manufacturers that are needed to conduct a final EUL risk-benefit assessment for global use of the vaccine,” a WHO official was quoted as saying by news agency.

Covaxin has demonstrated 77.8% effectiveness against symptomatic Covid-19 and 65.2% protection against the new Delta variant. Bharat Biotech said that it concluded the final analysis of Covaxin efficacy from Phase 3 trials.

TAGGED: Bharat Biotech, BHARAT BIOTECH COVAXIN, Covaxin, Covaxin News, COVAXIN SHELF LIFE
Share This Article
Twitter Email Copy Link Print
Previous Article IndiaJoy 2021 Inspires Over 30 VFX Global Experts IndiaJoy 2021 Inspires Over 30 Big VFX Global Experts
Next Article India's COVAXIN Gets WHO EUL Approval -Bharat Celebrates India’s COVAXIN Gets WHO Approval -Bharat Celebrates

Your Trusted Source for Accurate and Timely Updates!

We're committed to providing accurate and unbiased news as it unfolds, earning the trust of a large audience. Stay informed with our news updates on the latest events and trends, keeping you ahead of the curve.
FacebookLike
TwitterFollow
InstagramFollow

Popular Posts

3rd ODI Cricket: Virat Kohli, Suryakumar big hitting stun Australia

Ind Vs Aus 3rd ODI Cricket, was a nail biter which went up to the…

By TheNewsFacts

India’s BioE3 Policy Takes the Spotlight in Seoul

April 12, 2025: Seoul, South Korea – In a powerful pitch for sustainable innovation, India…

By TheNewsFacts

Vodafone Idea Shareholders heart burns as Share Price Down by 20.88%

Vodafone Idea’s share price took a big nose dive going down 20.88% on Tuesday to…

By TheNewsFacts

You Might Also Like

Bharat Biotech HILLCHOL
Latest News

Bharat Biotech’s Oral Cholera Vaccine HILLCHOL Demonstrates Success in Phase III Clinical Studies

By TheNewsFacts
Biovet Lumpy Skin Disease Vaccine Launched
Latest News

BIOLUMPIVAXIN: New Vaccine Now Available to Protect Livestock from LSD

By NewsFacts Bureau
Bharat Biotech
Latest News

Bharat Biotech’s New Therapies Bring Hope for Cancer and Genetic Disorders

By TheNewsFacts
Sapigen Biologix Mega Vaccine Plant in Odisha
Latest News

Singapore President Impressed by Sapigen Biologix Mega Vaccine Plant in Odisha

By TheNewsFacts
thenewsfacts thenewsfacts

About US


TheNewsFacts: Brings you the interesting facts, news facts and updates from India an the world across politics, tech, entertainment, business, tending, and more. We deliver what you love to read.
Top Categories
  • Latest News
  • Trending News
  • Paris Olympics 2024
  • Sports
  • Entertainment
  • Business
  • Technology
Usefull Links
  • About The News Facts
  • Latest News
  • Privacy Policy
  • Editorial Policy
  • Disclaimer
  • Contact Us
Follow us
Facebook Twitter Instagram

© thenewsfacts. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?